Analyst Price Target is $84.33
▲ +131.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Bright Minds Biosciences in the last 3 months. The average price target is $84.33, with a high forecast of $93.00 and a low forecast of $75.00. The average price target represents a 131.05% upside from the last price of $36.50.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Bright Minds Biosciences. This rating has held steady since December 2024, when it changed from a Strong Buy consensus rating.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Read More